Merck Secures $20M Upfront, $2.2B IBD Collaboration as Organon Sees 3% Revenue Drop
Merck secured a multi-year collaboration with Quotient Therapeutics, receiving $20 million upfront and up to $2.2 billion in milestone payments to develop inflammatory bowel disease targets via somatic genomics. Organon reported $6.2 billion in 2025 revenue, a 3% decline, while CEO resignation prompted governance reforms and flat 2026 guidance.
1. Merck-Quotient Collaboration
Merck entered a multi-year research agreement with Quotient Therapeutics, obtaining $20 million upfront and potential milestones totaling $2.2 billion to identify novel inflammatory bowel disease drug targets using Quotient’s somatic genomics platform. The collaboration aims to leverage high-resolution cellular data to accelerate target discovery and expand Merck’s immunology pipeline.
2. Organon Financial Performance
Organon’s full-year 2025 revenue reached $6.216 billion, down 3% year-over-year, driven by a 9% U.S. decline in Nexplanon and overall Established Brands erosion. Biosimilars grew 4% (5% ex-FX) on Hadlima strength, while Women’s Health revenue fell, and adjusted EBITDA totaled $1.907 billion with a 30.7% margin.
3. Leadership Transition at Organon
CEO Kevin Ali resigned following an internal probe into past Nexplanon sales practices, leading the board to emphasize internal controls and enhanced financial reporting. Joseph Morrissey, head of manufacturing and supply, was named interim CEO as investors assess the impact of governance changes on operational stability.
4. 2026 Guidance and Outlook
Organon guided 2026 revenue and adjusted EBITDA to be broadly flat with 2025 levels, reflecting continued cash generation without top-line growth. Management’s agenda centers on deleveraging, disciplined portfolio harvesting amid patent expirations, and selective reinvestment to sustain margins and mitigate pricing pressures.